Seven Fleet Capital Management LP
CIK
2092021
Location
MOUNTAIN VIEW, CA
Portfolio Value
Small
$177,773,650
Diversification
Diversified
Filing Date
Global Rank
#4,473
/ 8,622
▲ 579
· as of Mar 2026
Top Industry
Biotechnology
92.5%
3Y Alpha vs SPY
+96.4%
Period ended 4 months ago
Filed Jun 4, 2026 · 55d
2 quarters · since Dec 2025
Clone Performance
Feb 2026–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+41.5%
SPY
+9.0%
Annualised alpha
+94.5%
Max drawdown
−10.9%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 100% of reported value on average across 2 quarters. Past performance does not predict future results.
Portfolio Concentration
99 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
5.9%
−37.1 pts
Top 5
22.5%
−36.9 pts
Top 10
39.5%
−29.5 pts
HHI
243
Diversified−1,715
Portfolio Trend
2 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $177,773,650 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | +458,485 | 625,708 | $2,796,914 | |
| CTMX | CytomX Therapeutics, Inc. | +322,500 | 371,398 | $1,745,570 | |
| TNGX | Tango Therapeutics, Inc. | +286,840 | 502,012 | $10,502,091 | |
| SVRA | Savara Inc | +232,926 | 295,688 | $1,614,456 | |
| RLAY | Relay Therapeutics, Inc. | +184,738 | 257,738 | $2,564,493 | |
| AGIO | Agios Pharmaceuticals, Inc. | +177,809 | 209,547 | $7,088,975 | |
| AVTX | Avalo Therapeutics, Inc. | +150,476 | 213,819 | $3,192,317 | |
| CMPS | COMPASS Pathways plc | +118,021 | 158,021 | $873,856 | |
| PHVS | Pharvaris N.V. | +117,389 | 172,731 | $4,879,650 | |
| TYRA | Tyra Biosciences, Inc. | +116,125 | 195,685 | $7,494,735 | |
| VSTM | Verastem, Inc. | +108,260 | 123,400 | $654,020 | |
| LQDA | Liquidia Corp | +96,609 | 187,876 | $7,090,440 | |
| PCVX | Vaxcyte, Inc. | +83,085 | 108,450 | $6,302,029 | |
| KALV | KalVista Pharmaceuticals, Inc. | +80,075 | 128,487 | $2,586,443 | |
| ENTX | Entera Bio Ltd. | +70,224 | 205,542 | $228,151 | |
| ELVN | Enliven Therapeutics, Inc. | +64,077 | 164,030 | $6,429,976 | |
| CLYM | Climb Bio, Inc. | +54,254 | 130,654 | $894,979 | |
| CYTK | Cytokinetics Inc | +50,934 | 61,269 | $4,038,239 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | +39,607 | 54,258 | $4,553,331 | |
| LONA | LeonaBio, Inc. | +36,725 | 164,676 | $1,692,869 | |
| ABVX | Abivax S.A. | +29,553 | 43,052 | $4,793,840 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | +28,937 | 85,687 | $804,600 | |
| MLYS | Mineralys Therapeutics, Inc. | +27,546 | 69,571 | $1,884,678 | |
| TRVI | Trevi Therapeutics, Inc. | +20,039 | 27,149 | $323,887 | |
| GLUE | Monte Rosa Therapeutics, Inc. | +18,530 | 22,530 | $370,618 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
16 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | −1,439,393 | 75,758 | $5,127,301 | |
| GERN | Geron Corp | −353,700 | 424,180 | $632,028 | |
| IKT | Inhibikase Therapeutics, Inc. | −208,048 | 325,600 | $547,008 | |
| PALI | Palisade Bio, Inc. | −114,400 | 213,100 | $372,925 | |
| COGT | Cogent Biosciences, Inc. | −64,700 | 149,399 | $5,750,367 | |
| CMPX | Compass Therapeutics, Inc. | −51,775 | 516,972 | $2,734,781 | |
| XNCR | Xencor Inc | −29,554 | 80,000 | $964,800 | |
| ASMB | Assembly Biosciences, Inc. | −17,615 | 56,147 | $1,558,079 | |
| SLNO | Soleno Therapeutics Inc | −14,309 | 115,770 | $3,875,979 | |
| NKTR | Nektar Therapeutics | −10,700 | 4,300 | $309,385 | |
| NUVL | Nuvalent, Inc. | −10,529 | 2,072 | $212,276 | |
| PTGX | Protagonist Therapeutics, Inc | −4,000 | 4,000 | $421,600 | |
| EOLS | Evolus, Inc. | −3,943 | 78,057 | $320,814 | |
| CELC | Celcuity Inc. | −2,338 | 6,000 | $684,840 | |
| CGEM | Cullinan Therapeutics, Inc. | −1,156 | 1,844 | $26,203 | |
| BEAM | Beam Therapeutics Inc. | −733 | 8,804 | $209,799 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
25 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | 2,947,826 | $6,662,086 | |
| ERAS | Erasca, Inc. | 222,468 | $3,599,532 | |
| ROIV | Roivant Sciences Ltd. | 128,168 | $3,550,253 | |
| EPRX | Eupraxia Pharmaceuticals Inc. | 433,515 | $3,138,648 | |
| IDYA | IDEAYA Biosciences, Inc. | 86,283 | $2,874,949 | |
| DMRA | Damora Therapeutics, Inc. | 101,248 | $2,622,323 | |
| DFTX | Definium Therapeutics, Inc. | 99,887 | $1,887,864 | |
| CATX | Perspective Therapeutics, Inc. | 379,082 | $1,580,771 | |
| NERV | Minerva Neurosciences, Inc. | 248,476 | $1,497,067 | |
| ZLAB | Zai Lab Ltd | 77,858 | $1,464,508 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 82,890 | $1,212,680 | |
| AVBP | ArriVent BioPharma, Inc. | 50,252 | $1,159,313 | |
| LRMR | Larimar Therapeutics, Inc. | 256,585 | $1,154,632 | |
| IVA | Inventiva S.A. | 200,141 | $1,110,782 | |
| LPCN | Lipocine Inc. | 124,942 | $998,286 | |
| SYRE | Spyre Therapeutics, Inc. | 19,690 | $993,163 | |
| BCRX | Biocryst Pharmaceuticals Inc | 102,493 | $975,733 | |
| CLDX | Celldex Therapeutics, Inc. | 29,300 | $929,396 | |
| REPL | Replimune Group, Inc. | 120,400 | $921,060 | |
| MAZE | Maze Therapeutics, Inc. | 30,707 | $916,603 | |
| ALKS | Alkermes plc. | 24,170 | $854,651 | |
| ANTX | AN2 Therapeutics, Inc. | 199,701 | $682,977 | |
| DNLI | Denali Therapeutics Inc. | 35,286 | $677,491 | |
| UTHR | UNITED THERAPEUTICS Corp | 1,128 | $668,881 | |
| LLY | ELI LILLY & Co | 720 | $662,234 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
25 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TERN | Terns Pharmaceuticals, Inc. | 130,413 | $5,268,685 | |
| EXEL | Exelixis, Inc. | 68,569 | $3,005,379 | |
| BLTE | Belite Bio, Inc | 9,161 | $1,465,393 | |
| DYN | Dyne Therapeutics, Inc. | 70,180 | $1,372,720 | |
| FOLD | AMICUS THERAPEUTICS, INC. | 82,500 | $1,174,800 | |
| ZURA | Zura Bio Ltd | 166,500 | $872,460 | |
| PRAX | Praxis Precision Medicines, Inc. | 2,700 | $795,798 | |
| RLMD | Relmada Therapeutics, Inc. | 154,109 | $744,346 | |
| MBX | MBX Biosciences, Inc. | 18,200 | $574,028 | |
| ZYME | Zymeworks Inc. | 20,600 | $542,398 | |
| VRDN | Viridian Therapeutics, Inc.\DE | 14,654 | $456,032 | |
| NRIX | Nurix Therapeutics, Inc. | 20,000 | $379,400 | |
| PLRX | Pliant Therapeutics, Inc. | 276,500 | $337,330 | |
| ACRS | Aclaris Therapeutics, Inc. | 107,419 | $323,331 | |
| VKTX | Viking Therapeutics, Inc. | 6,000 | $211,080 | |
| QURE | uniQure N.V. | 8,742 | $209,196 | |
| ORKA | Oruka Therapeutics, Inc. | 5,240 | $158,824 | |
| NAMS | NewAmsterdam Pharma Co N.V. | 4,000 | $140,320 | |
| ALXO | Alx Oncology Holdings Inc | 117,817 | $133,133 | |
| RGC | Regencell Bioscience Holdings Ltd | 4,400 | $92,400 | |
| IMUX | Immunic, Inc. | 155,223 | $82,889 | |
| TRAW | Traws Pharma, Inc. | 49,260 | $55,663 | |
| VTGN | Vistagen Therapeutics, Inc. | 62,701 | $41,382 | |
| ENTA | Enanta Pharmaceuticals Inc | 2,270 | $35,797 | |
| ELDN | Eledon Pharmaceuticals, Inc. | 6,000 | $9,060 | |
| No positions match the current search. | ||||
99 tracked positions ·
$177,773,650 total
· as of Mar 31, 2026
Showing 1–50
of 99 positions by value
· page 1 of 2
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Added | 502,012 | $10,502,091 | 5.91% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 80,792 | $7,857,022 | 4.42% | |
| TYRA |
Tyra Biosciences, Inc.
Healthcare
|
Added | 195,685 | $7,494,735 | 4.22% | |
| LQDA |
Liquidia Corp
Healthcare
|
Added | 187,876 | $7,090,440 | 3.99% | |
| AGIO |
Agios Pharmaceuticals, Inc.
Healthcare
|
Added | 209,547 | $7,088,975 | 3.99% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
NEW | 2,947,826 | $6,662,086 | 3.75% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Added | 164,030 | $6,429,976 | 3.62% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Added | 108,450 | $6,302,029 | 3.54% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Reduced | 149,399 | $5,750,367 | 3.23% | |
| CGON |
CG Oncology, Inc.
Healthcare
|
Reduced | 75,758 | $5,127,301 | 2.88% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Added | 172,731 | $4,879,650 | 2.74% | |
| ABVX |
Abivax S.A.
Healthcare
|
Added | 43,052 | $4,793,840 | 2.70% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Added | 54,258 | $4,553,331 | 2.56% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Added | 61,269 | $4,038,239 | 2.27% | |
| SLNO |
Soleno Therapeutics Inc
Healthcare
|
Reduced | 115,770 | $3,875,979 | 2.18% | |
| ERAS |
Erasca, Inc.
Healthcare
|
NEW | 222,468 | $3,599,532 | 2.02% | |
| ROIV |
Roivant Sciences Ltd.
Healthcare
|
NEW | 128,168 | $3,550,253 | 2.00% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Added | 213,819 | $3,192,317 | 1.80% | |
| EPRX |
Eupraxia Pharmaceuticals Inc.
Healthcare
|
NEW | 433,515 | $3,138,648 | 1.77% | |
| IDYA |
IDEAYA Biosciences, Inc.
Healthcare
|
NEW | 86,283 | $2,874,949 | 1.62% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Added | 625,708 | $2,796,914 | 1.57% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
Added | 12,179 | $2,785,702 | 1.57% | |
| CMPX |
Compass Therapeutics, Inc.
Healthcare
|
Reduced | 516,972 | $2,734,781 | 1.54% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
NEW | 101,248 | $2,622,323 | 1.48% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
Added | 128,487 | $2,586,443 | 1.45% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Added | 257,738 | $2,564,493 | 1.44% | |
| AXSM |
Axsome Therapeutics, Inc.
Healthcare
|
Added | 14,055 | $2,375,576 | 1.34% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
NEW | 99,887 | $1,887,864 | 1.06% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
Added | 69,571 | $1,884,678 | 1.06% | |
| MDGL |
Madrigal Pharmaceuticals, Inc.
Healthcare
|
Added | 3,393 | $1,776,133 | 1.00% | |
| CTMX |
CytomX Therapeutics, Inc.
Healthcare
|
Added | 371,398 | $1,745,570 | 0.98% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Added | 164,676 | $1,692,869 | 0.95% | |
| SVRA |
Savara Inc
Healthcare
|
Added | 295,688 | $1,614,456 | 0.91% | |
| CATX |
Perspective Therapeutics, Inc.
Healthcare
|
NEW | 379,082 | $1,580,771 | 0.89% | |
| ASMB |
Assembly Biosciences, Inc.
Healthcare
|
Reduced | 56,147 | $1,558,079 | 0.88% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
NEW | 248,476 | $1,497,067 | 0.84% | |
| ZLAB |
Zai Lab Ltd
Healthcare
|
NEW | 77,858 | $1,464,508 | 0.82% | |
| TARS |
Tarsus Pharmaceuticals, Inc.
Healthcare
|
Added | 19,800 | $1,388,970 | 0.78% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
NEW | 82,890 | $1,212,680 | 0.68% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
NEW | 50,252 | $1,159,313 | 0.65% | |
| LRMR |
Larimar Therapeutics, Inc.
Healthcare
|
NEW | 256,585 | $1,154,632 | 0.65% | |
| KRYS |
Krystal Biotech, Inc.
Healthcare
|
Added | 4,316 | $1,114,909 | 0.63% | |
| IVA |
Inventiva S.A.
Healthcare
|
NEW | 200,141 | $1,110,782 | 0.62% | |
| LPCN |
Lipocine Inc.
Healthcare
|
NEW | 124,942 | $998,286 | 0.56% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
NEW | 19,690 | $993,163 | 0.56% | |
| BCRX |
Biocryst Pharmaceuticals Inc
Healthcare
|
NEW | 102,493 | $975,733 | 0.55% | |
| XNCR |
Xencor Inc
Healthcare
|
Reduced | 80,000 | $964,800 | 0.54% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
NEW | 29,300 | $929,396 | 0.52% | |
| REPL |
Replimune Group, Inc.
Healthcare
|
NEW | 120,400 | $921,060 | 0.52% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
NEW | 30,707 | $916,603 | 0.52% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.